EGFR and non-small cell lung carcinoma: The primary endpoint is disease‐free survival in patients who have undergone radical therapy (surgery and radiotherapy) or progression‐free survival in those receiving targeted therapy (first, second, and subsequent lines), chemotherapy (first and subsequent lines), combination therapy, and palliative/maintenance therapy according to stages of EGFR‐mutated NSCLC.